Jean-Jacques Kiladjian (Jean Jacques Kiladjian)

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 35

Top Topics

Inferior Vena Cava

Chronic Myeloid Leukemia

Top Venues

American journal of hematology

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Hannah Goulart, Lucia Masarova, Ruben A Mesa, Claire N Harrison, Jean-Jacques Kiladjian, Naveen Pemmaraju
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. British journal of haematology 205 (1) (2024)
Matteo Guerra, Hélène Pasquer, Rafael Daltro de Oliveira, Juliette Soret-Dulphy, Nabih Maslah, Lin-Pierre Zhao, Clémence Marcault, Marine Cazaux, Nicolas Gauthier, Emmanuelle Verger, Nathalie Parquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Bruno Cassinat, Jean-Jacques Kiladjian, Lina Benajiba
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM. American journal of hematology 99 (4) (2024)
Hannah Goulart, Lucia Masarova, Ruben A Mesa, Claire N Harrison, Jean-Jacques Kiladjian, Naveen Pemmaraju
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. British journal of haematology (2024)
Hannah Goulart, Lucia Masarova, Ruben A Mesa, Claire N Harrison, Jean-Jacques Kiladjian, Naveen Pemmaraju
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. British journal of haematology 205 (1) (2024)
Matteo Guerra, Hélène Pasquer, Rafael Daltro de Oliveira, Juliette Soret-Dulphy, Nabih Maslah, Lin-Pierre Zhao, Clémence Marcault, Marine Cazaux, Nicolas Gauthier, Emmanuelle Verger, Nathalie Parquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Bruno Cassinat, Jean-Jacques Kiladjian, Lina Benajiba
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM. American journal of hematology 99 (4) (2024)
Matteo Guerra, Hélène Pasquer, Rafael Daltro de Oliveira, Juliette Soret-Dulphy, Nabih Maslah, Lin-Pierre Zhao, Clémence Marcault, Marine Cazaux, Nicolas Gauthier, Emmanuelle Verger, Nathalie Parquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Bruno Cassinat, Jean-Jacques Kiladjian, Lina Benajiba
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM. American journal of hematology 99 (4) (2024)
Hannah Goulart, Lucia Masarova, Ruben A Mesa, Claire N Harrison, Jean-Jacques Kiladjian, Naveen Pemmaraju
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. British journal of haematology 205 (1) (2024)
Hannah Goulart, Lucia Masarova, Ruben A Mesa, Claire N Harrison, Jean-Jacques Kiladjian, Naveen Pemmaraju
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. British journal of haematology (2024)
Matteo Guerra, Hélène Pasquer, Rafael Daltro de Oliveira, Juliette Soret-Dulphy, Nabih Maslah, Lin-Pierre Zhao, Clémence Marcault, Marine Cazaux, Nicolas Gauthier, Emmanuelle Verger, Nathalie Parquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Bruno Cassinat, Jean-Jacques Kiladjian, Lina Benajiba
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM. American journal of hematology (2024)
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Carl Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian, null null
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia (2023)
Jean-Jacques Kiladjian, Bruno Cassinat
Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies. American journal of hematology (2023)
Jean-Jacques Kiladjian, Bruno Cassinat
MYELOPROLIFERATIVE NEOPLASMS AND SPLANCHNIC VEIN THROMBOSIS: CONTEMPORARY DIAGNOSTIC AND THERAPEUTIC STRATEGIES. American journal of hematology (2023)
John O Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Francesca Palandri, Timothy Devos, Francesco Passamonti, Raajit K Rampal, Adam J Mead, Gabriella Hobbs, Joseph M Scandura, Moshe Talpaz, Nikki Granacher, Tim C P Somervaille, Ronald Hoffman, Marielle J Wondergem, Mohamed E Salama, Gozde Colak, Jike Cui, Jean-Jacques Kiladjian, Alessandro Maria Maria Vannucchi, Srdan Verstovsek, Natalia Curto-García, Claire N Harrison, Vikas K Gupta
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Nabih Maslah, Lina Benajiba, Stephane Giraudier, Jean-Jacques Kiladjian, Bruno Cassinat
Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape. Leukemia (2023)
Jean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T Gerds, Vikas Gupta, Srdan Verstovsek, Miklos Egyed, Uwe Platzbecker, Jiří Mayer, Sebastian Grosicki, Árpád Illés, Tomasz Woźny, Stephen T Oh, Donal McLornan, Ilya Kirgner, Sung-Soo Yoon, Claire N Harrison, Barbara Klencke, Mei Huang, Jun Kawashima, Ruben Mesa
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials. HemaSphere 7 (11) (2023)
Vikas K Gupta, John O Mascarenhas, Marina Kremyanskaya, Raajit K Rampal, Moshe Talpaz, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Srdan Verstovsek, Gozde Colak, Debarshi Dey, Claire N Harrison
Matching-adjusted indirect comparison of pelabresib/ruxolitinib combination vs JAKi monotherapy in myelofibrosis. Blood advances (2023)
Nabih Maslah, Emmanuelle Verger, Stéphane Giraudier, Mathias Chea, Ronald Hoffman, John O Mascarenhas, Bruno Cassinat, Jean-Jacques Kiladjian
Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition. Blood advances 6 (9) (2022)
Graciela Rabadan Moraes, Florence Pasquier, Christophe Marzac, Erick Deconinck, Carlotta Caterina Damanti, Gwendoline Leroy, Mira El-Khoury, Wassim El Nemer, Jean-Jacques Kiladjian, Hana Raslova, Albert Najman, William Vainchenker, Caroline Marty, Christine Bellanné-Chantelot, Isabelle Plo
An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2 V617F myeloproliferative neoplasms. British journal of haematology 198 (1) (2022)
Ruben A Mesa, Claire Harrison, Stephen T Oh, Aaron T Gerds, Vikas K Gupta, John Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean-Jacques Kiladjian, Ewa Lech-Maranda, Donal P McLornan, Alessandro M Vannucchi, Uwe Platzbecker, Mei Huang, Bryan Strouse, Barbara J Klencke, Srdan Verstovsek
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia 36 (9) (2022)
Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Carl Hasselbalch, Robert Kralovics, Heinz Gisslinger, null null
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia 36 (5) (2022)
Matthieu Mosca, Gurvan Hermange, Amandine Tisserand, Robert John Noble, Christophe Marzac, Caroline Marty, Cécile Le Sueur, Hugo Campario, Gaëlle Vertenoeil, Mira El-Khoury, Cyril Catelain, Philippe Rameau, Cyril Gella, Julien Lenglet, Nicole Casadevall, Rémi Favier, Eric Solary, Bruno Cassinat, Jean-Jacques Kiladjian, Stefan N Constantinescu, Florence Pasquier, Michael E Hochberg, Hana Raslova, Jean-Luc J-L Villeval, Francois Girodon, William Vainchenker, Paul-Henry Cournede, Isabelle Plo
Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms. Blood 138 (22) (2022)
John O Mascarenhas, Heidi E Kosiorek, Josef T Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Abdulraheem Yacoub, Claire N Harrison, Mary Frances Frances McMullin, Alessandro Maria Maria Vannucchi, Joanne Ewing, Casey L O'Connell, Jean-Jacques Kiladjian, Adam J Mead, Elliott F Winton, David S Leibowitz, Valerio De Stefano, Murat O Arcasoy, Craig M Kessler, Rosalind Catchatourian, Damiano Rondelli, Richard T Silver, Andrea Bacigalupo, Arnon Nagler, Marina Kremyanskaya, Max Fine Levine, Juan Esteban Arango Ossa, Erin M McGovern, Lonette Sandy, Mohamad E Salama, Vesna Najfeld, Joseph Tripodi, Noushin Farnoud, Alexander V Penson, Rona Singer Weinberg, Leah Price, Judith D Goldberg, Tiziano Barbui, Roberto Marchioli, Gianni Tognoni, Raajit K Rampal, Ruben A Mesa, Amylou C Dueck, Ronald Hoffman
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood 139 (19) (2022)
Claire N Harrison, Vikas K Gupta, Aaron T Gerds, Raajit K Rampal, Srdan Verstovsek, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben A Mesa, Andrew T Kuykendall, Alessandro Maria Maria Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Eric Jourdan, Marielle J Wondergem, Haifa Kathrin Al-Ali, Veronika Buxhofer-Ausch, Alberto Álvarez-Larrán, Andrea Patriarca, Marina Kremyanskaya, Adam J Mead, Sanjay Akhani, Yuri Sheikine, Gozde Colak, John O Mascarenhas
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future oncology (London, England) 18 (27) (2022)
Srdan Verstovsek, Haifa Kathrin Al-Ali, John O Mascarenhas, Andrew Charles Perkins, Alessandro Maria Maria Vannucchi, Sanjay R Mohan, Bart L Scott, Dariusz Woszczyk, Steffen Koschmieder, Regina García-Delgado, Rejtő László, Jesse S McGreivy, Wayne P Rothbaum, Jean-Jacques Kiladjian
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis. Future oncology (London, England) (2022)
John O Mascarenhas, Hélène F E Gleitz, Helen T Chifotides, Claire N Harrison, Srdan Verstovsek, Alessandro Maria Vannucchi, Raajit K Rampal, Jean-Jacques Kiladjian, William Vainchenker, Ronald Hoffman, Rebekka K Schneider, Alan F List
Biological drivers of clinical phenotype in myelofibrosis. Leukemia (2022)
Nabih Maslah, Odonchimeg Ravdan, Louis Drevon, Emmanuelle Verger, Célia Belkhodja, Christine Chomienne, Bruno Cassinat, Jean-Jacques Kiladjian, Stéphane Giraudier, Marie-Hélène Schlageter
Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement. British journal of haematology (2021)
John O Mascarenhas, Rami S Komrokji, Francesca Palandri, Bruno Martino, Dietger Niederwieser, Andreas Reiter, Bart L Scott, Maria R Baer, Ronald Hoffman, Olatoyosi Odenike, Alessandro M Vannucchi, Jacqueline Bussolari, Eugene Zhu, Esther Rose, Laurie Sherman, Souria Dougherty, Libo Sun, Fei Huang, Ying Wan, Faye M Feller, Aleksandra Rizo, Jean-Jacques Kiladjian
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (26) (2021)
Ralfs Buks, Tracy Dagher, Maria Giustina Rotordam, David Monedero Alonso, Sylvie Cochet, Emilie-Fleur Gautier, Philippe Chafey, Bruno Cassinat, Jean-Jacques Kiladjian, Nadine Becker, Isabelle Plo, Stéphane Egée, Wassim El Nemer
Altered Ca 2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis. Cells 11 (1) (2021)
Srdan Verstovsek, Chih-Cheng Chen, Miklós Egyed, Martin Ellis, Maria Laura Fox, Yeow T Goh, Vikas K Gupta, Claire Harrison, Jean-Jacques Kiladjian, Mihaela C Lazaroiu, Adam J Mead, Donal McLornan, Mary Frances Frances McMullin, Stephen T Oh, Andrew Charles Perkins, Uwe Platzbecker, Christof Scheid, Alessandro Maria Maria Vannucchi, Sung-Soo Yoon, Mark M Kowalski, Ruben A Mesa
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future oncology (London, England) 17 (12) (2021)
Clémence Marcault, Lin-Pierre Zhao, Nabih Maslah, Emmanuelle Verger, Rafael Daltro de Oliveira, Juliette Soret-Dulphy, Marine Cazaux, Nicolas Gauthier, Blandine Roux, Emmanuelle Clappier, Nathalie Parquet, Christine Dosquet, Delphine Rea, Jean-Marc Zini, William Vainchenker, Emmanuel Raffoux, Stéphane Giraudier, Jean-Jacques Kiladjian, Bruno Cassinat, Lina Benajiba
Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms. Blood 138 (21) (2021)
Jean-Jacques Kiladjian, Tiziano Barbui
From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera? Leukemia 34 (11) (2020)
Sylvie Tondeur, Franciane Paul, Jérémie Riou, Olivier Mansier, Dana Ranta, Lenaïg Le Clech, Eric Lippert, Suzanne Tavitian, Driss Chaoui, Mélanie Mercier, Benoit De Renzis, Laurane Cottin, Bruno Cassinat, Jean-Marie Chrétien, Jean-Christophe Ianotto, Olivier Allangba, Christophe Marzac, Laurent Voillat, Françoise Boyer, Corentin Orvain, Mathilde Hunault-Berger, François Girodon, Jean-Jacques Kiladjian, Valérie Ugo, Damien Luque Paz
Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study. Leukemia 35 (3) (2020)
Moshe Talpaz, Jean-Jacques Kiladjian
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia 35 (1) (2020)
Pierre Fenaux, Jean-Jacques Kiladjian, Uwe Platzbecker
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood 133 (8) (2019)
Barbara Mora, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Daniela Barraco, Alessandro Rambaldi, Marianna Caramella, Rami S Komrokji, Jean-Jacques Kiladjian, Jason Gotlib, Alessandra Iurlo, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T Silver, Francesco Albano, Giulia Benevolo, Chiara Cavalloni, Silvia Uccella, Raffaella Accetta, Claudia Siracusa, Stefania Agnoli, Michele Merli, Tiziano Barbui, Lorenza Bertù, Mario Cazzola, Alessandro Maria Maria Vannucchi, Francesco Passamonti
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. American journal of hematology 95 (1) (2019)
Emmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, Christine Dosquet, Stephane Giraudier, Marie-Hélène Schlageter, Jean-Christophe Ianotto, Mohammed A Yassin, Nader Al-Dewik, Serge Carillo, Eric Legouffe, Valerie Ugo, Christine Chomienne, Jean-Jacques Kiladjian
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood 126 (24) (2015)